INTRODUCTION:
Annual influenza epidemics and episodic pandemics continue to cause widespread illness and mortality. Strategies to prevent and treat acute influenza infection have remained limited to seasonal influenza vaccination and a small arsenal of antiviral drugs. Thus, there is an urgent need for additional prophylactic and therapeutic options, including new targets and mechanisms of action, to address the considerable challenges posed by the rapid evolution of influenza viruses that limit the effectiveness of vaccines and the emergence of antiviral drug resistance.
RATIONALE:
The recent characterization of broadly neutralizing antibodies (bnAbs) against influenza virus identified the highly conserved hemagglutinin (HA) stem as a promising target for development of universal vaccines and complementary therapeutics. Even though this spurred several bnAbs to be evaluated as passive immunotherapy in clinical trials, antibodies are large and complex molecules that are generally unsuited for oral delivery. We therefore set out to utilize the structural details of the molecular interactions and mechanisms of HA stem bnAbs to identify an orally active small molecule that mimics bnAb functionality. Influenza A viruses can be separated in group 1 and group 2 on the basis of their HA subtype (H1 to H18), and anti-stem bnAbs usually bind to group 1 or to group 2 viruses, but a few can target both.
RESULTS: We screened a diverse chemical library for compounds that selectively target the group 1 HA epitope of bnAb CR6261 through a binding assay that detects displacement of a CR6261-based designed small protein. Benzylpiperazines were identified as a major hit class, with JNJ7918 being the most promising candidate. Consistent with its binding to the functional HA stem epitope, this compound also neutralized influenza infection in vitro. Key chemical modifications were subsequently introduced to optimize binding and neutralization potency, as well as properties dictating metabolic stability and oral bioavailability, to finally afford JNJ4796. This lead compound binds and neutralizes a broad spectrum of influenza A group 1 viruses in vitro and protects mice against lethal and sublethal influenza challenge after oral administration. The compound also effectively neutralizes virus infection in reconstituted three-dimensional cell culture of fully differentiated human bronchial epithelial cells. Like bnAb CR6261, the mechanism of action of JNJ4796 was demonstrated to be based on inhibition of the pHsensitive conformational change of HA that triggers fusion of the viral and endosomal membranes and release of the viral genome into the host cell. Cocrystal structures with H1 and H5 HAs reveal that JNJ4796 recapitulates the original CR6261-HA hotspot interactions and provide detailed and valuable information on the minimal epitope in the HA1-HA2 fusion region of the stem for an antiviral small molecule to neutralize influenza A group 1 viruses.
CONCLUSION:
We identified an orally active small molecule against influenza A HA that mimics the binding and functionality of the broadly neutralizing antibody CR6261. The small molecule targets the conserved HA stem region, acts as a fusion inhibitor by inhibiting conformational changes that lead to the postfusion HA structure, and neutralizes a broad spectrum of human pandemic, seasonal, and emerging group 1 influenza A viruses. Thus, the compound holds promise as an urgently sought-after therapeutic option offering a complementary mechanism of action to existing antiviral drugs for the treatment of influenza virus infection, and that should further aid development of universal therapeutics that prevent entry of influenza virus in host cells.
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usion peptide Recent characterization of broadly neutralizing antibodies (bnAbs) against influenza virus identified the conserved hemagglutinin (HA) stem as a target for development of universal vaccines and therapeutics. Although several stem bnAbs are being evaluated in clinical trials, antibodies are generally unsuited for oral delivery. Guided by structural knowledge of the interactions and mechanism of anti-stem bnAb CR6261, we selected and optimized small molecules that mimic the bnAb functionality. Our lead compound neutralizes influenza A group 1 viruses by inhibiting HA-mediated fusion in vitro, protects mice against lethal and sublethal influenza challenge after oral administration, and effectively neutralizes virus infection in reconstituted three-dimensional cell culture of fully differentiated human bronchial epithelial cells. Cocrystal structures with H1 and H5 HAs reveal that the lead compound recapitulates the bnAb hotspot interactions.
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he World Health Organization estimates that annual influenza epidemics cause around 3 million to 5 million cases of severe illness and up to 650,000 deaths worldwide (1, 2). Seasonal influenza vaccination still remains the best strategy to prevent infection, but the vaccines that are available now offer a very limited breadth of protection. The discovery of human broadly neutralizing antibodies (bnAbs) to influenza virus provides hope for the development of broad-spectrum, universal vaccines (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) . Because of the high level of conservation of their epitopes in the hemagglutinin (HA) stem, these bnAbs neutralize a wide range of viruses within and across influenza virus subtypes. Their binding prevents the pH-induced conformational changes in HA that are required for viral fusion in the endosomal compartments of target cells in the respiratory tract (6) (7) (8) (9) (10) (11) (13) (14) (15) . Efforts have therefore been made to develop vaccination modalities aimed at directing the immune response to the HA stem through different vaccination regimens (16, 17) , sequential vaccination with different chimeric HA constructs (18, 19) , and administration of stem-based immunogens (20) (21) (22) (23) (24) . In addition, several bnAbs themselves are being evaluated in clinical trials as passive immunotherapy (25) . Another recent strategy to prevent influenza infection stems from development of a highly potent multidomain antibody with almost universal breadth against influenza A and B viruses that can be administered intransally in mice using adeno-associated virus-mediated gene delivery (26) .
Therapeutic options to treat acute influenza infection also include antiviral drugs directed at blocking virus uncoating during cell entry (M2 proton channel inhibitors) and progeny release from infected cells (neuraminidase inhibitors) (27, 28) . However, resistance to antiviral drugs is an emerging problem, owing to the high mutation rate in influenza viruses and their genetic reassembly possibilities (29) . New antiviral drugs (30, 31) and combination therapies (32, 33) , with alternative mechanisms of action against alternative viral targets are therefore urgently needed.
Small-molecule drugs, in contrast to antibodies, offer the advantage of oral bioavailability, high shelf stability, and relatively low production costs.
Influenza A viruses have been classified into 18 hemagglutinin subtypes (H1 to H18), which can be divided phylogenetically into two groups (1 and 2), and 11 neuraminidase subtypes (N1 to N11). Antibody CR6261 broadly neutralizes most group 1 influenza A viruses (7, 9) . Cocrystal structures of CR6261 in complex with H1 HA (7, 9) stimulated the design of small-protein ligands of about 10 kDa that target the conserved stem region. These small proteins mimic the antibody interactions with HA and inhibit influenza virus fusion (34) (35) (36) . Cocrystal structures of bnAbs FI6v3 and CR9114 with HAs (6, 14) further enabled the design of even smaller peptides as influenza fusion inhibitors (37) . However, neither small proteins nor peptides generally are orally bioavailable.
Development of small-molecule ligands directed at antibody binding sites is challenging. Antibody epitopes, as for other protein-protein interfaces, are generally flat, large, and undulating (~1000 to 2000 Å 2 ) (38), in stark contrast to the small concave pockets (typically in the 300 to 500 Å 2 range), which are common as targets for small-molecule drugs (39) . Moreover, to mimic the function of an HA-stem bnAb, a functional small molecule should reproduce the key interactions that lead to fusion inhibition. We have therefore identified and optimized small molecules with such properties through application of a strategy that was guided by detailed knowledge of the binding mode and molecular mechanism of bnAb CR6261 (7, 15) and encouraged by earlier successes in the design of small proteins and peptidic ligands targeted to the HA stem (34, 35, 37) .
High-throughput screening and optimization
To identify potent small molecules that mimic group 1 bnAb CR6261, in terms of breadth of binding (7, 9, 35) , virus neutralization, and mechanism (Fig. 1A) , we screened for compounds that selectively target the CR6261 epitope on HA. We applied the AlphaLISA (amplified luminescent proximity homogeneous assay) technology in competition mode as our high-throughput screening (HTS) method (Fig. 1B) . A diverse library of 500,000 small-molecule compounds was screened for displacing HB80.4, which is a CR6261-based computationally designed small protein with very similar binding mode and fusion inhibition profile (34, 35) . HB80.4 was used instead of CR6261, because avidity effects leading to higher apparent affinity of the bivalent antibody would have resulted in a more stringent and thus less sensitive assay. This approach biased the screen toward compounds that act via the desired mechanism of action. About 9000 small molecules with weak to medium binding capacity were initially retrieved; binding of 300 compounds was confirmed through repeated testing and via the Truhit AlphaLISA counter assay that can identify false-positive hits.
Benzylpiperazines emerged as a major hit class, with JNJ7918 being the most promising candidate with a median inhibitory concentration (IC 50 (Fig. 2) . No competition with H1 HA head-binding antibody 2D1 (40) was detected against H1/Cal, further validating the HA-stem specificity ( Fig. 2A) . Key chemical modifications to increase molecular interactions with the HA stem, that is, introduction of a functional group at the benzylic position and modification of the phenyl with a propargyl moiety (Fig. 2B) , greatly improved binding (~30-to 80-fold) to HAs from H1/Cal, H1N1 A/ New Caledonia/20/1999 (H1/NCa), H1N1 A/ Brisbane/59/2007 (H1/Bris), and H5/Viet, as exemplified by the second-generation compound JNJ6715 (Fig. 2C) . Moreover, virus neutralization assays with a panel of H1 and H5 influenza strains, which represent human pandemic, seasonal, and emerging viruses in influenza A group 1, demonstrated improved neutralization (~30-to 500-fold). Like bnAb CR6261, JNJ6715 showed heterosubtypic neutralization of group 1 viruses without measurable cytotoxicity in Madin-Darby canine kidney (MDCK) cells ( Fig.  2D and table S1 ).
In vitro and in vivo pharmacokinetic profiling
Further in vitro profiling of JNJ6715 revealed poor kinetic aqueous solubility of 11.3 mM at pH 7.4 and poor metabolic stability of >346 ml/min per kilogram based on intrinsic clearance in mouse and human liver microsomes, making this compound unsuitable for in vivo testing (Fig. 3A) . To enhance its drug-like properties, we replaced the methyl ester functionality at the benzylic position with a 2-methyl oxadiazole group, substituted the central phenyl by pyridine, and replaced the 6-methoxy benzothiazole with a 5-trifluoromethoxy-benzoxazole group, generating JNJ8897. The compound was further optimized to generate JNJ4796 by replacing the 2-methyl oxadiazole group with 2-methyl tetrazole and the trifluoromethoxy group with methyl amide (Fig. 3B) . These modifications reduced the intrinsic clearance in mouse and human liver microsomes for both compounds while sustaining virus neutralization [median effective concentration (EC 50 ) for H1/Cal and H1/NCa of 0.064 and 0.076 mM for JNJ8897, and 0.066 and 0.038 mM for JNJ4796]. In particular, JNJ4796 demonstrated substantially reduced human and murine intrinsic clearance (Fig. 3 , A and C) and increased aqueous solubility, which translated to a favorable in vivo pharmacokinetics profile with compound half-life (t 1/2 ) in mice of 2.4 hours after oral administration. The overall bioavailability for this compound was 30.0%, with a plasma concentration reaching 1152 ng/ml, equivalent to 2.1 mM, after oral administration at 10 mg/kg (mg of JNJ4796 per kg of body weight) (Fig. 3A) . Testing JNJ4796 in a diverse panel of pharmacologically relevant receptors, ion channels, and transporters showed that the compound does not substantially inhibit any of these potential off-targets (table S2) .
Oral efficacy against influenza infection
In line with its in vitro neutralizing activity and acceptable pharmacokinetics data, oral administration of JNJ4796 protected mice from lethal challenge of 25 times the median lethal dose (LD 50 ) of H1N1 A/Puerto Rico/8/1934 virus (Fig.  3D) . Doses of 50 and 10 mg/kg of JNJ4796 twice daily, initiated one day before challenge and continuing for 7 days, resulted in 100% survival at day 21 in comparison to the less potent compound JNJ8897, for which less than 50% survival was achieved (day 21 survival was 40% for 50 mg/ kg and 25% for 10 mg/kg) ( Fig. 3D and tables S3 and S4). JNJ4796 only partly alleviated morbidity in this stringent H1N1 infection model, as demonstrated by animal weight loss. Nevertheless, dose-dependent reversal of weight loss was observed at the study end for both 50 mg/kg and 10 mg/kg of JNJ4796 (Fig. 3D ). Oral doses of JNJ4796 also resulted in dose-dependent efficacy after a sublethal viral challenge (LD 90 ), with twice daily administration of 15 and 5 mg/kg of JNJ4796 giving rise to 100% survival and only moderate weight loss effects that were moreover restricted to the period directly after treatment ( fig. S1 and tables S3 and S4).
To assess the potential practical utility of JNJ4796 in the context of human airway infection, the neutralization capacity of JNJ4796 was evaluated in a reconstituted three-dimensional cell culture of fully differentiated human bronchial epithelial cells (HBECs) derived from a pool of donors. This model system recapitulates several relevant characteristics of human airway target tissue, such as production of mucus, cilia beating, and local metabolic activity (41) 
Group 1 binding specificity and mechanism of JNJ4796
Like bnAb CR6261, JNJ4796 further demonstrated heterosubtypic group 1 HA binding and virus neutralization breadth without cytotoxicity (Fig.  4 , A and B; fig. S3 ; and tables S1 and S5). CR6261 neutralizes group 1 influenza A viruses by inhibiting the low-pH-induced HA conformational change, which triggers fusion of the viral and endosomal membranes and release of the viral genome into the host cell (42) . Each HA monomer is composed of two subunits (HA1 and HA2). CR6261 and JNJ4796 bind components of both HA1 and HA2 in the trimeric HA stem, thereby stabilizing the prefusion conformation of HA and preventing conformational rearrangements in the HA stem that lead to the postfusion structure. This inhibition is demonstrated in two different experiments. First, in a conformational change inhibition assay (Fig. 4C ), JNJ4796 dosedependently prevents pH-induced transition of HA to the postfusion conformation and subsequent loss of the HA1 subunit after reduction of the interchain HA disulfide. Second, the protease-susceptibility assay indicates that, like the stem-targeting bnAbs, compound JNJ4796 stabilizes the prefusion conformation and blocks the HA conformational change at low pH and the subsequent susceptibility to trypsin (43) (Fig. 4D ).
Crystallographic analysis of JNJ4796-HA complexes
To decipher the structural basis for its mechanism of action and broad group 1 specificity, (6, 7, 14) . JNJ4796 occupies the same hydrophobic groove as CR6261, where hydrophobic residues from the heavychain complementarity-determining regions (HCDRs) and framework region 3 (HFR3), including HCDR2 signature residues Ile 53 and Phe 54 encoded by the germline gene V H 1-69, insert into the binding site (Fig. 5C ). JNJ4796 contacts this hydrophobic groove through both hydrophobic and polar interactions ( Fig. 5E and fig. S5 ). The substituted benzoxazole moiety (A-ring; the rings A to E are depicted in Fig. 5D . This triad of rings, C to E, locks the conformation of Trp 21 , which is important in the fusion process (46, 47) . Overall, JNJ4796 buries~453 Å 2 (on H1) and 472 Å 2 (on H5) of surface at the HA interface, completely enveloping the central hydrophobic groove as compared with more discontinuous coverage by stem-targeting bnAbs (CR6261, FI6v3, and CR9114) (Fig. 5F ). The structural basis for the~25-fold decreased binding affinity of JNJ4796 to H5 HA compared with H1 HA was elucidated by comparing the crystal structures of JNJ4796 bound to H1/SI06 and H5/Viet HAs (Fig. 6, A to F) . The A-and Erings of JNJ4796 have higher thermal mobility when bound to H5 as compared with H1 HA (Fig.  6D) . The presence of Val 40 in H1 HA allows for a more stable interaction of the A-ring with the hydrophobic groove, whereas the corresponding Gln 40 in H5, with its longer and more flexible side chain, does not interact as tightly, thereby increasing the dynamics of the bound A-ring that contributes to the higher thermal mobility of JNJ4796 (Fig. 6, A to D) . The E-ring is relatively solvent-exposed in both HA-JNJ4796 complexes but is rotated~180°in H5 compared with H1 HA (Fig. 5F ). Another key difference pertains to the B-ring, where the pyridine moiety is displaced outward by~0.4 Å in the H5-JNJ4796 complex, resulting in slightly weaker interactions compared with the H1-JNJ4796 complex (Figs. 5E and 6E).
To rationalize the inability of JNJ4796 to bind with group 2 HAs, the apo structure of group 2 HA H3N2 A/Hong Kong/1/1968 (H3/HK68) was compared with group 1 HA (H1/SI06) bound to JNJ4796. The key differences in the epitope of the small molecule on H1 HA with the corresponding region on H3 HA are the presence of a glycosylation site at HA1 Asn 38 (Fig. 6, G to I) . The stem-targeting bnAbs FI6v3 and CR9114 are able to reorient the glycan and accommodate these helix-A differences to acquire pan-influenza reactivity, whereas bnAbs CR6261 and F10 are unable to do so and exhibit group 1 specificity. The different orientations of these antibodies on the HA surface also reflect their different breadths for group 1 and group 2 HAs (48). JNJ4796 is probably also unable to reorient the Asn 38 glycan and accommodate the helix-A mutations and, therefore, would experience steric clashes with group 2 H3 HA (Fig. 6 , G to I) that could account for its group 1 specificity.
Conclusions
Although antibodies are increasingly recognized as effective therapeutics, they may fail to achieve broad applicability in some settings owing to inconvenience in administration and relatively high cost. Therefore, replacing antibodies with small molecules is desirable. Here we present proof of concept for antibody-guided, small-molecule discovery. Starting from a well-characterized antibody with a desired activity profile, we selected and further improved a small-molecule "antibody mimetic" that recapitulates the antibody features in vitro and in vivo. We demonstrated the feasibility of targeting the conserved stem epitope on influenza HA with the orally bioavailable small molecule JNJ4796 with comparable high affinity and breadth of binding to bnAb CR6261. The compound mimics the key interactions observed in the antibody-HA cocrystal structures, inhibits the pH-sensitive conformational change of HA, neutralizes influenza viruses in vitro, and protects mice from lethal viral challenge. The success of this approach demonstrates the advantage of rigorously considering the targeted epitope-specific binding activity in close combination with the associated functional activity and mechanism of action, instead of focusing on potency alone. This strategy allows for the generation of robust van structure-activity relationships, thereby yielding a great level of control over the pharmacodynamic and pharmacokinetic properties of the selected ligand classes.
Material and Methods
Expression and purification of the hemagglutinin for binding and x-ray crystallography Hemagglutinin (HA) proteins for binding and crystallographic studies were expressed using a baculovirus system as described previously (49, 50) . Briefly, each HA was fused with gp67 signal peptide at the N terminus and to a BirA biotinylation site, thrombin cleavage site, trimerization domain, and His-tag at the C terminus. The HAs were purified using metal affinity chromatography using Ni-NTA resin. For binding studies, each HA was biotinylated with BirA and purified by gel filtration chromatography. For crystallization studies, each HA was treated with trypsin (New England Biolabs, 5mU trypsin per mg HA, overnight at 4°C) to produce uniformly cleaved HA (HA1/HA2), and to remove the trimerization domain and His-tag. The cleaved material was purified by gel filtration.
Site-specific modification of the HA for conformational change inhibition assay HA constructs were designed with a Sortase A recognition motif (LPETG) between the trimerization domain and C-terminal His-tag to allow site-specific modification via Sortase A mediated transpeptidation (37) . Expi293F cells (Thermo Fischer) were transfected with a pcDNA2004 mammalian expression plasmid encoding the modified HA protein, according to manufacturer's instructions. The cell culture supernatant was harvested 7 days posttransfection. Soluble HA was purified from clarified supernatant via a three-step purification protocol: HisTrap Excel (GE Healthcare Life Sciences), HisTrap HP (GE Healthcare Life Sciences), and finally Superdex 200 Size Exclusion (GE Healthcare Life Sciences). Purified HA proteins were biotinylated using a peptide-based Sortase A recognition sequence, GGGGGK-Biotin (Pepscan). The labeling reaction was performed as described previously (51) . Excess peptide and Sortase A were separated from the modified HA via Superdex 200 Size Exclusion (GE Healthcare Life Sciences). For the conformational change assay, the uncleaved HA (HA0) was cleaved into HA1 and HA2 by incubation with trypsin (Trysin EDTA, Gibco), and the reaction was stopped by addition of Trypsin Inhibitor (Gibco).
Expression and purification of mini-protein HB80.4
DNA encoding HB80.4-His was cloned into pET29b(+) (Novagen) and expressed using Rosetta (DE3) cells (Novagen) and auto-induction Magic Media (ThermoFisher). Bacteria were grown to an optical density at 600 nm (OD600) of~0.6 at 37°C and then at 25°C overnight. Periplasmic extracts were obtained using BugBuster protein extraction reagent (EMD Millipore) according to the manufacturer's specifications. HB80.4 was purified from periplasmic extract using HisTrap FF (GE Healthcare Life Sciences) followed by dialysis with PBS pH 7.4 (Gibco). Purity was determined by SDS-PAGE and was >95%.
Human antibodies and influenza viruses for assays
Fully human IgG1 antibodies CR6261 (7), CR9114 (6), and CH65 (52) were expressed and purified as described previously (8 
AlphaLISA competition assay
Small-molecule (SM) compounds were dissolved at 5 mM in 100% DMSO and threefold serially diluted in 100% DMSO nine times in 96-well, half-area microtiter plates. The compounds were further diluted 1:40 in assay buffer (PBS, 0.05% BSA, 0.05% Tween-20) and subsequently spun down for 15 min at 1000g to separate any insoluble material. 10 ml of the diluted compounds were incubated for 60 min with 10 ml HA biotinylated with a Lightning Link kit (Innova Biosciences, 2.5 nM in assay buffer) in white 96-well, half-area untreated plates (PerkinElmer), after which 10 ml of His-labeled competitor protein HB80.4 (diluted in assay buffer) was added, followed by another 60-min incubation, addition of 10 ml of anti-His acceptor beads (PerkinElmer; 50 mg/ml in assay buffer), and a third 60-min incubation. Finally, 10 ml of streptavidin donor beads (PerkinElmer; 50 mg/ml in assay buffer) were added, followed by 60-min incubation before the plates were read in a microplate reader at 615 nm (Biotek Synergy Neo). Eight copies of samples containing no compound, with and without HA, were prepared for each plate and served as high and low controls, respectively. The sigmoidal inhibition curves were fitted with a robust four-parameter logistic model to derive IC 50 values. For the high-throughput screen, only a single concentration of the SM compounds was tested (final concentration of 30 mM).
Truhit AlphaLISA counter assay
Threefold serially diluted SM compounds dissolved in 100% DMSO were screened using the TruHits kit (PerkinElmer) following the manufacturer's instructions. The compounds were tested in the same dilutions as described in the AlphaLISA competition assay (assay buffer: PBS, 0.05% BSA, 0.05% Tween-20). Eight copies of samples containing no compound, with and without HA, were prepared for each plate and served as high and low controls, respectively.
Cell toxicity assay
MDCK cells (ATCC CCL-34) were maintained in Dulbecco's Modified Eagle Medium (DMEM, Gibco) supplemented with 10% fetal bovine serum and 2 mM L-glutamine at 37°C, 10% CO 2 . On the day of the experiment, MDCK cells were seeded in 2× infection medium (DMEM, 1× L-glutamine, 6 mg/ml trypsin-EDTA) at 25,000 cells/well (50 ml) in white opaque 96-well plates (BD Falcon). The 96-well plates containing threefold serially diluted compounds were further diluted 1:10 in incomplete medium (DMEM, 1× L-glutamine) and subsequently spun down (1000g, 15 min). A volume of 12 ml was added to 48 ml incomplete medium in a fresh 96-well plate (96-well sterile cell culture plate, V-bottom, Greiner). Then, 50 ml of the compound solution was added to the MDCK plate followed by incubation for 96 hours at 37°C, 10% CO 2 . After incubation, cell viability was measured by adding 70 ml of ATPlite 1step reagent (PerkinElmer) to the wells. Luminescence was measured in a Biotek Synergy neo plate reader.
Virus neutralization assay (VNA)
Threefold serial dilutions of the SM compounds were prepared as described above. On the day of the experiment, MDCK cells were seeded in 2× infection medium (DMEM, 1× L-glutamine, 6 mg/ ml trypsin-EDTA) in white opaque 96-well plates at 25,000 cells/well. A 10× predilution of the SMs was prepared in incomplete medium (DMEM, 1× L-glutamine). CR6261 was diluted to 15 mM in incomplete medium and serially diluted 1:3 nine times. Subsequently, the SMs and CR6261 were spun down at 1000g for 15 min. After spinning, 12 ml supernatant was added to 48 ml of the respective virus dilutions in incomplete medium in a 96-well plate. Two solvent controls, with and without virus, were setup for each sample. Then, 50 ml of the virus/SM mixture was added to the van cells followed by incubation for 4 days at 37°C under 10% CO 2 . After incubation, 70 ml of ATPlite 1step (PerkinElmer) was added to the wells and the plate read for luminescence.
Conformational change inhibition assay (CCI)
Threefold serial diluted SM compounds were prepared as described in the AlphaLISA competition assay above and further diluted 1:100 in assay buffer (PBS, 1% BSA, 0.1% Tween-20). White, half-area, high-binding, 96-well plates (Perkin Elmer) were coated overnight with 50 ml 0.5 mg/ml streptavidin (Pierce) in PBS (Gibco). The plates were washed (150 ml PBS, 0.05% Tween-20) and blocked by exposing them to assay buffer for 1 hour. Subsequently, plates were incubated for 60 min with 50 ml sortase biotinylated, trypsin-EDTA (Gibco) cleaved HA (0.1 mg/ml in assay buffer). After 60 min, the plates were washed, and 50 ml of the diluted compounds were added to the plates for 60 min while shaking. Then, 10 ml 1M acetate pH 5.25 was added to induce HA conformational changes, followed by 20-min incubation at room temperature on a shaking platform. The plates were washed followed by addition of 2.5 mM DTT (diluted in PBS) to reduce any postfusion HA and remove HA1. To detect the presence or absence of HA1, after 60-min incubation on a shaking platform, plates were washed followed by incubation with 0.5 mg/ml HA1 head-binding antibody CH65-HRP (labeled with Lightning Link HRP, Innova Biosciences) in assay buffer for 60 min. The plates were washed, and 50 ml of POD substrate (Roche) was added followed by luminescence read out on a Biotek Synergy Neo plate reader. Total inhibition of the low-pH induced HA conformational change was achieved by using HA stem-binding bnAbs CR6261 or CR9114 (4 nM) as a positive control. Complete conformational change of the HA was achieved at low pH in presence of a nonbinding IgG1 control (40 nM).
Kinetic solubility
SM compounds were dissolved in DMSO to obtain 5 mM DMSO stock solutions. Stock solutions were diluted in duplicate into the required buffers (pH 4.0 and pH 7.4) to a final maximum concentration of 100 mM in 2% DMSO/buffer. Sample plates were gently shaken for 4 hours at room temperature. The samples were centrifuged and the supernatants were transferred to a new plate and diluted 1:1 with HCL/ACN for UPLC analysis. Reference and analyte samples were analyzed by UPLC/UV using a generic UPLC method. The measured solubilities are presented as mean values of duplicate determinations, with a maximum solubility threshold of 100 mM, and the lower limit of quantitation governed by the UV absorption properties of the compound. microsomes (male CD mice). Microsomes (final protein concentration 0.5 mg/ml), 0.1 M phosphate buffer pH 7.4 containing 1 mM MgCl 2 and SM compound (final substrate concentration 1 mM; final DMSO concentration 0.05%) were preincubated at 37°C prior to the addition of NADPH (final concentration 1 mM) to initiate the reaction. The final incubation volume was 500 ml. Three species-specific control compounds were included with each species. All incubations were performed singularly for each SM. At six time points (0, 5, 10, 20, 40, and 60 min), reactions were stopped by transferring 50 ml of the incubation mixture into methanol. SM compound concentrations were analyzed by LC-MS/MS and the resulting data used to determine the half-life and intrinsic clearance of the compound in each species.
Plasma protein binding
The free and bound fractions of the SM compound in mouse and human plasma was determined by rapid equilibrium dialysis (RED device, Thermo Fisher Scientific, Geel, Belgium). The RED device consists of a 48-well plate containing disposable inserts bisected by a semipermeable membrane creating two chambers. A 300-ml aliquot of plasma containing SM compound at 5 mM was placed one side and 500 ml of phosphate buffered saline (PBS) on the other. The plate was sealed and incubated at approximately 37°C for 4.5 hours. Samples were removed from both the plasma and buffer compartment and analyzed for the SM compound using a specific LC-MS/MS method to estimate free and bound concentrations.
In vivo pharmacokinetics
The pharmacokinetic profiles of the SM compounds were evaluated in fed male BALB/c mice (n = 3/group). Mice were i.v. injected with the SM compound at 2.5 mg/kg, formulated as a 0.25 mg/ml solution in 20% w/v hydroxypropylbeta-cyclodextrin pH 6.5, and blood samples were collected from the saphenous vein at 0.08, 0.17, 0.5, 1, 2, 4, 7, and 24 hours into EDTAcontaining microcentrifuge tubes. The compound was administered p.o. at 10 mg/kg, formulated as 1.33 mg/ml solution in 20% w/v hydroxypropylbeta-cyclodextrin pH 6.5, and blood samples were collected from the saphenous vein at 0.5, 1, 2, 4, 7, 12, and 24 hours into EDTA-containing microcentrifuge tubes. The blood samples were immediately centrifuged at 4°C, and the plasma was stored at −20°C. SM compound concentrations from the plasma samples were analyzed using LC-MS/MS. Individual plasma concentrationtime profiles were subjected to a noncompartmental pharmacokinetic analysis (NCA) using Phoenix WinNonlin version 6.3 (Certara, NJ, USA).
In vitro selectivity profiling
The binding selectivity of the SM compounds at concentration of 10 mM was assessed in a panel of 52 radioactive ligand displacement assays (Eurofins Cerep SA) as per the providers' validated protocols. Results were expressed as percent inhibition of control specific binding. Inhibition values higher than 50% were considered to represent significant effects.
Mouse influenza challenge
Dosing formulations for the SM compounds were freshly prepared on the day before administration by dissolving the SM compound in cyclodextrin (40% hydroxypropyl-beta-cyclodextrin). The SM compound (7.5 ml/kg per animal) was administered twice daily per os (p.o. ) to remove mucus and cell debris. Cells were infected with H1N1 A/Puerto Rico/8/1934 at an MOI of 0.1 and concomitantly treated with a JNJ4796 at different concentrations. Cells were treated both at the apical and basolateral side of the tissue culture. After 1 hour of incubation, virus and compounds administered to the apical compartment were removed to reconstitute the air-liquid interface, whereas cells remained exposed to JNJ4796 through the basolateral compartment. Sham-treated (PBS supplemented with DMSO at a final concentration identical to compound-treated samples) and mock-infected wells were taken along as positive and negative controls, respectively. For each experimental condition, four biological replicates were included. Ninety-six hours postinfection, apical washes (D-PBS, 200ml/insert) of the epithelium were used to determine the amount of released viral RNA by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR).
Trypsin susceptibility (TS) assay
In the TS assay, 5 mM H1/PR8 HA was preincubated separately with 25 mM of JNJ4796 and 10 mM CR6261 Fab for~30 min at room temperature. Control reactions were incubated with 2% DMSO. The pH of each reaction was lowered using 1 M sodium acetate buffer (pH 5.0). One reaction was retained at pH 7.4 to assess digestion at neutral pH. The reaction solutions were then thoroughly mixed and incubated for about 30 min at 37°C. After incubation, the reaction solutions were equilibrated at room temperature, and the pH was neutralized by addition of 200 mM Tris buffer, pH 8.5. Trypsin-ultra (NEB Inc.) was added at final ratio of 1:50 by mass and the samples were digested for about 40 min at 37°C. After incubation with trypsin, the reaction solutions were equilibrated at room temperature and quenched by addition of nonreducing SDS buffer and boiled for 2 min at 100°C. All samples were analyzed by 4-20% SDS-PAGE gel and imaged using BioRad ChemDoc imaging system.
Surface plasmon resonance (SPR)
All SPR experiments were performed using a Biacore T200 instrument operating at 25°C. Biotinylated HA was covalently immobilized on a streptavidin-coated, carboxymethylated dextran sensor surface (SA chip, GE Healthcare). JNJ4796 was dissolved at 10 mM in 100% DMSO and then diluted in the running buffer [20 mM PBS, 137 mM NaCl, 0.05% P-20 surfactant, pH 7.4 (GE Healthcare), supplemented with 2% DMSO]. Binding constants were obtained from a series of injections of JNJ4796 from 0.1 nM to 1 mM with a flow rate of 30 ml/min. Data from single-cycle kinetics were analyzed using BIAevaluation software. Base lines were adjusted to zero for all curves, and injection start times were aligned. The reference sensorgrams were subtracted from the experimental sensorgrams to yield curves representing specific binding followed by background subtraction (i.e., double-referencing). Binding kinetics was evaluated using a 1:1 binding model (Langmuir) to obtain association rate constants (k a ) and dissociation rate constants (k d ). Binding affinity (K D ) was estimated from the concentration dependence of the observed steady-state responses.
Thermodynamic binding profile
Biotinylated HA was purified using a spin-column to remove excess biotin and covalently immobilized on a streptavidin-coated, carboxymethylated dextran sensor surface (SA chip, GE Healthcare). JNJ4796 was dissolved at 10 mM in 100% DMSO and diluted in the running buffer [20 mM PBS, 137 mM NaCl, 0.05% P-20 surfactant, pH 7.4 (GE Healthcare), supplemented with 2% DMSO]. Binding constants were obtained from a series of injections of JNJ4796 from 0.1 nM to 10 mM in five half-log serial dilutions, individually injected at the following temperatures: 10°, 15°, 25°, 35°, and 40°C, at a flow rate of 30 ml/min. Experiments were performed in duplicate (for H1/NCa) or triplicate (for H1/Bri) to ensure reproducibility. Data from single-cycle kinetics were analyzed using BIAevaluation software (GE Healthcare). Base lines were adjusted to zero for all curves, and injection start times were aligned. The reference sensorgrams were subtracted from the experimental sensorgrams to yield curves representing specific binding followed by background subtraction (i.e., double-referencing).
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Binding kinetics was evaluated using a 1:1 binding model (Langmuir) to obtain association rate constants (k a ) and dissociation rate constants (k d ). Binding affinity (K D ) was estimated from the concentration dependence of the steadystate responses observed. Changes in thermodynamic parameters enthalpy (DH) and entropy (DS) were calculated from the slope and intercept, respectively, of the temperature dependence of the dissociation constant using the van't Hoff approximation: lnK D = −DH/R·T + DS/R, where R is the gas constant and T is the absolute temperature. The binding free energy, DG, was derived from the Gibbs-Helmholtz equation (DG = DH − DT · S).
Crystallization and structure determination of the JNJ4796-HA complexes
Gel filtration fractions containing H1/SI06 and H5/Viet HAs were concentrated to~10 mg/ml in 20 mM Tris, pH 8.0, and 150 mM NaCl. Compound JNJ4796 at~5 molar excess was incubated with the HAs for~1 hour at room temperature and centrifuged at 14,000g for 2 to 3 min before setting up crystallization trials. Crystallization screens used the sitting drop vapor diffusion method with our automated CrystalMation robotic system (Rigaku) at TSRI. Within 3 to 7 days, diffraction quality crystals had formed in 0.2 M disodium hydrogen phosphate, 20% w/v PEG3350 at 20°C (for H1/SI06) and 0.2 M lithium sulfate, 20% w/v PEG3350 at 4°C (for H5/Viet). The resulting crystals were cryoprotected with 5-15% ethylene glycol, flash cooled, and stored in liquid nitrogen until data collection. Diffraction data were collected at 100 K on the Stanford Synchrotron Radiation Lightsource beamline 12-2 and processed with HKL-2000 (54) . Initial phases were determined by molecular replacement using Phaser (55, 56) with HA models corresponding to PDB codes 1RU7 (for H1/SI06) and 4FQI (for H5/Viet). Refinement was carried out in Phenix (57) , and alternated with manual rebuilding and adjustment in COOT (58) . The final coordinates were validated using MolProbity (59) . Data collection and refinement statistics are summarized in table S6.
Structural analyses
Surface areas buried on the HA upon binding of JNJ4796 were calculated with the Protein Interfaces, Surfaces and Assemblies (PISA) server at the European Bioinformatics Institute (60) . MacPyMol (DeLano Scientific) was used to render structure figures.
Statistics
Inhibition potencies in AlphaLISA, viral neutralization and conformational change inhibition assays were determined by robust four-parameter logistic (4PL) regression routines in SPSS (IBM) or R (www.R-project.org). The inflection point (C value) of the curve is taken as the IC 50 value. A transform-both-sides (TBS, square root) approach, robust regression techniques (including Huber's M) and the optional inclusion of the low and high control values as anchor points were used to stabilize the variance, down-weigh outliers, and to fit incomplete curves, respectively. For reasons of presentation, results and curves were scaled from 0 to 100% that represent the range between the robust averages of the low and high control values. For the H1N1 A/Puerto Rico/8/1934 in vivo challenge studies, the differences in survival (as compared to vehicle control) were tested using a two-sided Fisher's exact test. The significance of the differences was adjusted for multiple testing by Holm-Bonferroni adjustment for the compounds at their highest dose (within the two studies in which the compounds were investigated), followed by a step-wise approach for lower doses. Statistical analysis of bodyweight was based on area under the curve (AUC) analysis. For this analysis, the last observed bodyweight was carried forward if a mouse died during follow-up of the study. Briefly, the weight per mouse at day 0 was used as baseline, and weight change was determined relative to baseline. The AUC was defined as the summation of the area above and below the baseline. Differences in net AUC's were tested in a one-way analysis of variance (ANOVA) with the same test strategy and post hoc adjustment as mentioned for survival. Statistical analyses were performed using SAS version 9.4 (SAS Institute Inc., USA) and SPSS version 20 (SPSS Inc., USA). Statistical significance level was set at a = 0.05. For studies performed on HBEC cultures, results were statistically analyzed by ANOVA between the log titers and the (categorized) concentrations. The significance is based on the contrasts between the values of each of the three highest concentration with the aggregated results for the concentrations in the lower plateau.
